

Tuberculosis profile: Brunei Darussalam

Population 2022: 0.45 million

Estimates of TB burden*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	260 (220-300)	57 (49-66)
HIV-positive TB incidence	7 (2-15)	1.6 (0.51-3.2)
MDR/RR-TB incidence**	1 (0-2)	0.29 (0.06-0.51)
HIV-negative TB mortality	23 (20-27)	5.1 (4.4-6)
HIV-positive TB mortality	0 (0-1)	0.1 (0-0.33)

Estimated proportion of TB cases with MDR/RR-TB*, 2022

New cases	0.37% (0.13-0.73)
Previously treated cases	2.3% (0.37-5.8)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2022	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2022	9% (7-11)

TB case notifications, 2022

Total new and relapse	224
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	65%
- % pulmonary	80%
- % bacteriologically confirmed ^	91%
- % children aged 0-14 years	2%
- % women (aged ≥15 years)	31%
- % men (aged ≥15 years)	67%
Total cases notified	224

TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive	4	2.7%
- on antiretroviral therapy	4	100%

Drug-resistant TB care**, 2022

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	39%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	0
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	0
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	0

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	70%	229
Previously treated cases, excluding relapse, registered in 2021		0
HIV-positive TB cases registered in 2021	40%	5
MDR/RR-TB cases started on second-line treatment in 2020		0
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020		

TB preventive treatment, 2022

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	4.1% (4-4.2)

* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.


** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

^ Calculated for pulmonary cases only


^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)



HIV-negative TB mortality (Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2022 (Number)



Cases attributable to five risk factors, 2022 (Number)

